

SPLIT			
\$sitecode	User:	System Date:	Mode: Development
Site Name:			

Rejection (REJ)

Version: 5.0; 11-30-07

Segment (*PROTSEG*):Date of first treatment (*REJDATE*):

Diagnosis

Diagnosis of rejection based on:

- Clinical (signs & symptoms): (*REJDXCLI*) ☐ No - 0 ☐ Yes - 1
- Biochemical: (*REJDXBIO*) ☐ No - 0 ☐ Yes - 1
- Biopsy: (*REJBIOPP*) ☐ No - 0 ☐ Yes - 1
Type of rejection: (*REJTYPER*) ☐ Acute - 1 ☐ Chronic - 2

4. Chemistries at time of rejection diagnosis:

	Common Units (CU)	Standard International (SI)
Total bilirubin	(<i>REJTOBIL</i>) _____ (xxx.x) mg/dL	(<i>REJTOBIS</i>) _____ (xxxxx.x) μmol/L
Direct bilirubin	(<i>REJDIBIL</i>) _____ (xxx.xx) mg/dL	(<i>REJDIBIS</i>) _____ (xxxxx.xx) μmol/L
AST/SGOT	(<i>REJAST</i>) _____ (xxxxx) IU/L	
ALT/SGPT	(<i>REJALT</i>) _____ (xxxxx) IU/L	
Alkaline Phosphatase	(<i>REJAP</i>) _____ (xxxx) IU/L	
Gamma-Glutamyltransferase	(<i>REJGG</i>) _____ (xxxx) IU/L	
Sodium	(<i>REJSOD</i>) _____ (xxx) IU/L	

Medications

5. Maintenance Immunosuppression treatment before rejection diagnosis:

Steroids: (REJMTSTE) ☐ No - 0 ☐ Yes - 1

Tacrolimus: (REJMTTAC) ☐ No - 0 ☐ Yes - 1

CsA: (REJMTCSA) ☐ No - 0 ☐ Yes - 1

Mycophenolate Mofetil: (REJMTMYC) ☐ No - 0 ☐ Yes - 1

Azathioprine: (REJMTAZA) ☐ No - 0 ☐ Yes - 1

Sirolimus: (REJMTRAP) ☐ No - 0 ☐ Yes - 1

Other: (REJMTOTH) ☐ No - 0 ☐ Yes - 1

If *Other*, specify: (REJMMOTH)

6. Rejection Therapy:

Pulse steroids (REJRPLST) ☐ No - 0 ☐ Yes - 1

Tapered steroids (REJRTPST) ☐ No - 0 ☐ Yes - 1

ALG/ATG/ALS (REJRALG) ☐ No - 0 ☐ Yes - 1

OKT3/Monoclonal (REJROKT3) ☐ No - 0 ☐ Yes - 1

IL-2 Mab (REJRMAB) ☐ No - 0 ☐ Yes - 1

Tacrolimus (REJRTAC) ☐ No - 0 ☐ Yes - 1

CsA (REJRCSA) ☐ No - 0 ☐ Yes - 1

Mycophenolate Mofetil (REJRMYC) ☐ No - 0 ☐ Yes - 1

Azathioprine (REJRAZA) ☐ No - 0 ☐ Yes - 1

Sirolimus (REJRRAP) ☐ No - 0 ☐ Yes - 1

Other (REJROTH) ☐ No - 0 ☐ Yes - 1

If *Other*, specify: (REJMPOTH)

Thirty-Day Status

7. Outcome of this rejection at 30 days: (REJOUTCM)

Complete response - 1
 Partial Response - 2
 No response - 3
 Retransplant candidate - 4
 Patient death - 5

8. Was this a steroid resistant rejection episode? (REJSRREP) ☐ No - 0 ☐ Yes - 1

9. Chemistries 30 days post rejection treatment initiated:

	Common Units (CUI)	Standard International (SI)
Total bilirubin	(REJ30TB) _____ (xxx.x) mg/dL	(REJ30TSI) _____ (xxxxx.x) μmol/L
Direct bilirubin	(REJ30DB) _____ (xxx.xx) mg/dL	(REJ30DSI) _____ (xxxxx.xx) μmol/L
AST/SGOT	(REJ30AST) _____ (xxxxx) IU/L	
ALT/SGPT	(REJ30ALT) _____ (xxxxx) IU/L	
Alkaline Phosphatase	(REJ30AP) _____ (xxxx) IU/L	
Gamma-Glutamyltransferase	(REJ30GG) _____ (xxxx) IU/L	
Sodium	(REJ30SOD) _____ (xxx) IU/L	

The Notes field should not be used to communicate information to the SPLIT DCC. This field is intended to be used for notes center staff may find useful when returning to the form.

Notes: (REJCOMME)



